linjc16/ctgov huggingface dataset:
Treatment of Actinic Keratoses With Photodynamic Therapy Using Sunlight Versus Red Light

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to evaluate the use of sunlight instead of red light during photodynamic therapy of actinic keratoses using methyl aminolevulinate

Conditions
-----------------
Actinic Keratoses

Intervention / Treatment
-----------------
* Procedure: photodynamic therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: symmetric actinic keratoses in scalp or face Exclusion Criteria: porphyria, pregnancy, breast feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: photodynamic therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Measurement of Activity Participation for Persons With Schizophrenia Living in the Community

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to develop a questionnaire on community occupational participation for persons with schizophrenia living in the community. In the International Classification of Functioning, Disability, and Health (ICF) recently revised by World Health Organization, activity participation is recognized as an important indication of health-related status. From the perspective of occupational therapy, the researcher intends to investigate the experiences of occupational participation among schizophrenic patients living in the community, and to develop a measuring tool for occupational participation accordingly. The development of the Community Occupational Participation Questionnaire will be based on the result of a qualitative research project which the researcher is carrying out at the moment. The resultant questionnaire will provide a quantitative measure of community occupational participation for persons with schizophrenia, as well as a measurement tool of activity participation for health-related research studies. Furthermore, it may provide valuable information to the development of community psychiatric services. This current study will take one year. Tasks to be accomplished include: building item pool, examining content validity of each item, pilot testing, item analysis, norm establishment, and testing reliability and validity. Data will be collected in different areas of Taiwan, and will be analyzed with the following methods: content validity ratio, item-total correlation, Cronbach's alpha, and confirmatory factor analysis. The study will result in an occupational participation questionnaire with norm, validity and reliability.

Detailed Description
-----------------
First, the participants were informed the right and how to fill the self-report survey questionnare in. And then they began to complete the questionnare. After finishing it, the participants gave the questionnare back to the examinor and got a gift as a reward.

Conditions
-----------------
Schizophrenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: person with Schizophrenia Must be able to read Chinese Majorly living in community

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Development and Testing of a Generic Screening for Use in Application Process of Medical Rehabilitation Services

Study Overview
=================
Brief Summary
-----------------
The primary objective of this research is the development and testing of a brief cross-indication instrument (screening) for use in the approval process of medical rehabilitation services. In addition to the empirical foundation, this generic instrument should have a high level of acceptance of both applicants and payers of rehabilitation services. Furthermore, an everyday and economic use for the routine application process for medical rehabilitation services at the German statutory pension insurance scheme should be provided. In the first study phase, a long instrument was tested with a sample of rehabilitees that received approval of medical rehabilitation services. This assessment including the measurement of rehabilitation-related somatic, psychological and social impairments was first tested for its psychometric properties and then reduced to a short instrument (screening) using quantitative methods. In the second study phase, the then-existing screening will be part of the application documents for medical rehabilitation services to assess its management properties and practicability in everyday use of the German statutory pension insurance scheme.

Official Title
-----------------
Entwicklung Und Testung Eines Generischen Screenings für Die Vorabschätzung Von Fallgruppen im Antragsverfahren

Conditions
-----------------
Medical Rehabilitation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Member of German Federal Pension Insurance Approval of a medical rehabilitation according to § 15 SGB VI Exclusion Criteria: Returning questionnaire after beginning of medical rehabilitation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Comorbid symptoms<br> | |
| No comorbid symptoms<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| return-to-work | The outcome is assessed by the discharge report from the rehabilitation centre. | up to 9 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| therapies during rehabilitation | The outcome is assessed by the discharge report from the rehabilitation centre according to the 'classification of therapeutical services'. | up to 9 months | 
| socio-medical prognosis | The outcome is assessed by the discharge report from the rehabilitation centre. | up to 9 months |
Perioperative Oral Steroids for Chronic Rhinosinusitis Without Polyps (CRSsNP)

Study Overview
=================
Brief Summary
-----------------
While oral steroids have been shown to be effective in the management of patients with chronic rhinosinusitis with polyps, its role in treating chronic rhinosinusitis without polyps (CRSsNP) is ambiguous. Despite a lack of strong clinical evidence to suggest a benefit in this disease state, steroids are often prescribed as a component of post-operative care after sinus surgery for patients without polyps. Oral steroids carry with them significant adverse effects, and should be prescribed thoughtfully. The aims of this study are to determine if oral steroids in the peri-operative period improves patient outcomes in CRS without polyps.

Official Title
-----------------
The Role of Perioperative Systemic Steroids in Patients With Chronic Rhinosinusitis Without Polyps (CRSsNP)

Conditions
-----------------
Chronic Rhinosinusitis, Endoscopic Sinus Surgery, Chronic Rhinosinusitis Without Polyps, Oral Steroids

Intervention / Treatment
-----------------
* Drug: Prednisone
* Drug: Flonase


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CRSsNP as defined by Clinical Practice Guideline (Update) on Adult Sinusitis scheduled to undergo endoscopic sinus surgery Exclusion Criteria: chronic rhinosinusitis with polyps (CRSwNP) Aspirin exacerbated respiratory disease Cystic fibrosis Immunosuppressive states (Human immunodeficiency virus, transplant) Oral steroid use within 30 days of surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Prednisone<br>Provided oral steroid and topical steroid | Drug: Prednisone<br> <br> Drug: Flonase<br> <br> |
| Placebo Comparator: Placebo<br>Provided oral placebo and topical steroid | Drug: Flonase<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sino-nasal Outcome Test (SNOT-22) Over Time | SNOT-22 is a validated scale which measures sinonasal symptoms for sinusitis patients. The 22 questions are rated on a scale of 0-5 for a maximum total score of 110. Higher scores represent more symptomatic patients. | Baseline, 1, week, 1 month, 3 months, and 6 months | 
| Lund Kennedy Endoscopy Score Over Time | The Lund-Kennedy score is a validated scale by which clinicians grade the endoscopic appearance of the sinonasal cavity for sinusitis patients. There are 5 parameters rated on a scale of 0-2 for each side of the nose, for a maximum total score of 20 points. Higher scores represent a worse endoscopic appearance. | Baseline, 1, week, 1 month, 3 months, and 6 months |
Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent head and neck cancer

Official Title
-----------------
Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer

Conditions
-----------------
Head and Neck Cancer

Intervention / Treatment
-----------------
* Drug: Paclitaxel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with locally advanced head and neck cancer pretreated with surgery and/or radiotherapy and not suitable for further radical local treatment or patients with distant metastases who may have received no or one chemotherapy regimen Exclusion Criteria: Patients with serious, uncontrolled medical illness

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Paclitaxel<br> | Drug: Paclitaxel<br>* Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent<br>* Other names: BMS-181339;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate [defined as total number of patients with complete and partial response divided by number of response-evaluable patients] based on predetermined evaluation criteria |  | Each 49 day course of treatment until withdrawal or unacceptable toxicity | 
| Safety: incidence and severity of adverse events, laboratory test abnormalities |  | Each 49 day course of treatment until withdrawal or unacceptable toxicity | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of response, defined as either Complete or Partial Response, based on Evaluation Criteria on Therapeutic Effects in Patients with Advanced or Recurrent Breast Cancer |  | Each 49 day course of treatment until withdrawal or unacceptable toxicity |
Effects of Transcranial Magnetic Stimulation to the Cerebellum on Cognition

Study Overview
=================
Brief Summary
-----------------
Functional neuroimaging studies have shown that the cerebellum is active during cognitive performance. The investigators hypothesize that stimulation of the cerebellum with transcranial magnetic stimulation will produce brief changes in performance of the task, suggesting that cerebellar activation is necessary for normal cognitive function.

Official Title
-----------------
fMRI and TMS Analysis of Cerebellar Cognitive Function

Conditions
-----------------
Cognitive Performance

Intervention / Treatment
-----------------
* Device: Cerebellar transcranial magnetic stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 19-30 years of age Informed consent Exclusion Criteria: History of seizure or a family history of epilepsy History of stroke Presence of metal anywhere in the head except the mouth Presence of cardiac pacemakers Presence of cochlear implants Presence of implanted medication pump History of heart disease Presence of intracardiac lines Increased intracranial pressure, such as after infarctions or trauma Children, or outside of age range Pregnancy Currently taking tricyclic anti-depressants or neuroleptic medication History of head trauma History of respiratory disease

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: Sham TMS<br>A Sham TMS coil, designed to elicit sham cerebellar transcranial magnetic stimulation, is used to administer sham TMS pulses after letters are presented. | Device: Cerebellar transcranial magnetic stimulation<br>* single pulse TMS or repetitive TMS at 1 Hz frequency<br>|
| Experimental: TMS<br>A genuine TMS coil is used to administer cerebellar transcranial magnetic stimulation pulses after letter presentation. | Device: Cerebellar transcranial magnetic stimulation<br>* single pulse TMS or repetitive TMS at 1 Hz frequency<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Behavioral performance (accuracy, or rate of conditioned responses) |  | during computerized task performance (2 hours) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reaction time |  | during performance of computerized task (2 hours) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TMS, fMRI, verbal working memory, classical conditioning, eyeblink, classical eyeblink conditioning, Healthy subjects, Memory
Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection

Study Overview
=================
Brief Summary
-----------------
Gastric cancer radical surgery related complications are common.Somatostatin is a conventional medical therapy for bleeding.This study explore the effect of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node dissection.

Official Title
-----------------
Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection -a Prospective Randomized Controlled Study

Conditions
-----------------
Gastric Cancer After D2 Lymph Node Dissection

Intervention / Treatment
-----------------
* Drug: Somatostatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: More than eighteen years old Gastric cancer diagnosed by pathological examination Be given informed consent Without diabetes/hyperthyroidism/Damages of functions of heart, liver and kidney/Systemic Infection/immunodeficiency Exclusion Criteria: Contraindication of vascular puncture operation Patients who refused to take part in the programe Poor compliance of treatment Malnutrition,BMI<18 with pancreatectomy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Somatostatin group<br>Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical therapy. | Drug: Somatostatin<br>* Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.<br>|
| Placebo Comparator: Blank group<br>Use the normal saline instead of somatostatin. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fistula of pancreas | number of patients | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| amount of bleeding | amount of bleeding after the operation | six months | 
| seroperitoneum | seroperitoneum volum of patients | six months | 
| infection of incisional wound | number of patients | one year |
Can the Hypertrophy of Contralateral Testis Predict the Absence of the Non-palpable Testis in the Boys Aged From 6months to 18months of Age ?

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to verify whether the hypertrophy of contralateral testis may predict the absence of the non-palpable testis in the boys younger than 24months of age. According to the previous studies of other countries, the large size of the contralateral testis of the nonpalpable testis has positive correlation woth the weak viability of the affected testis. We are going to evaluate this hypothesis with prospective study. 3 groups are going to be enrolled into this study ; non-palpable testis group(Group1), palpable but not normally descended testis group(group2) and control group(group3). The size of testis will be measured with Ultrasound and the length, width and the height will be measured before surgery at outpatient department. For the group 1 & 2, the viability of the affected testis will be evaluated and compared after surgery. In addition the comparison with normal control group is also going th be conducted.

Conditions
-----------------
Focus of Study

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: neonates or Infants who visited the out-patient clinic with nonpalpable or undescended testis.(group 1, 2) aged from 6months to 18months neonates or Infants aged from 6months to 18months with normal testis (volunteers, Group3) Exclusion Criteria: previous history of hormonal therapy. chromosomal abnormality previous history of abdomen or inguinal area surgery children diagnosed with epididymitis or orchitis twin baby infants with premature (<37 weeks) birth history

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 18 Months

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| control<br>healthy children with normal bilateral testis | |
| undescended palpable testis<br>patient whose affected testis is not descended to the normal position but palpable and exist intact in the upper area | |
| non-paplpable testis<br>patient whose affected testis is not palpable during the physical examination | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Size of contralateral testis | The testicular size is measured 3-dimensionally with ultrasonography. The length, width and height will be measured and the volume of testis will be evaluated. | 1 day of initial visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cryptorchidism, undescended testis, hypertrophy of contralateral testis
Access to Care and Adherence Tuberculosis (TB) Survey

Study Overview
=================
Brief Summary
-----------------
Prompt access to care and treatment adherence are the hearth of tuberculosis control. This is a multicentre observational prospective study aimed at studying the factors associated with delayed access to care and low adherence to anti-tuberculosis treatment. Hetero- and self-administered questionnaires will be used at enrollment to assess clinical presentation and time and modalities of the diagnosis. Treatment adherence will be assessed during the follow-up with self administered questionnaires.

Official Title
-----------------
Survey Nazionale Sui Determinanti Del Ritardato Accesso Alle Cure e Della Mancata Aderenza al Trattamento Antitubercolare (National Survey on the Determinats of Delayed Access to Care and Non-adherence to Tuberculosis Treatment)

Conditions
-----------------
Tuberculosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >= 18 yrs of age recent new TB diagnosis Tuberculosis treatment prescribed Ability to sign the informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to TB diagnosis |  | Study enrollment |